NCT04491721View on ClinicalTrials.gov

Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

Enrolling by invitationOBSERVATIONAL

Enrollment

407

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

June 30, 2027

Study Completion Date

July 31, 2027

Conditions

Diffuse Large B Cell Lymphoma

Trial Locations (1)

Unknown

Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing

All Listed Sponsors

lead

Chinese Academy of Medical Sciences

OTHER